Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Rhea-AI Summary

Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss its financial results and highlights.

Interested parties can access the live call via telephone by dialing toll-free 800-715-9871 for domestic callers. The live webcast can be accessed through the 'Events & Presentations' section of Oncocyte's website. A replay of the webcast will be available on the company's website shortly after the call concludes.

Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m. ET

IRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on Thursday, August 8, 2024, at 5:00 p.m. Eastern Time to discuss its financial results and highlights.

Interested parties may access the live call via telephone by dialing toll free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.

The live webcast of the call may be accessed by visiting the “Events & Presentations” section of the Company’s website at https://investors.oncocyte.com. A replay of the webcast will be available on the Company’s website shortly after the conclusion of the call.

CONFERENCE CALL DETAILS

Participant Toll-Free Dial-In Number: (800) 715-9871
Participant Toll Dial-In Number: +1 (646) 307-1963
Conference ID: 4153469

Webcast

https://events.q4inc.com/attendee/478523544

About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:

VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/ 
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/ 
GraftAssure™ - https://oncocyte.com/graftassure/ 
DetermaIO™ - https://oncocyte.com/determa-io/ 
DetermaCNI™ - https://oncocyte.com/determa-cni/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

Contact:
Jeff Ramson

PCG Advisory

(646) 863-6893

jramson@pcgadvisory.com

FAQ

When will Oncocyte (OCX) release its Q2 2024 financial results?

Oncocyte (OCX) will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close.

What time is Oncocyte's (OCX) Q2 2024 earnings call scheduled for?

Oncocyte's (OCX) Q2 2024 earnings call is scheduled for Thursday, August 8, 2024, at 2:00 p.m. PT / 5:00 p.m. ET.

How can I access Oncocyte's (OCX) Q2 2024 earnings call?

You can access Oncocyte's (OCX) Q2 2024 earnings call by dialing toll-free 800-715-9871 for domestic callers, or by visiting the 'Events & Presentations' section of the company's website for the live webcast.

What is the conference ID for Oncocyte's (OCX) Q2 2024 earnings call?

The conference ID for Oncocyte's (OCX) Q2 2024 earnings call is 4153469.